Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 186 participants.

Also called NCT05347693

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 186 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05347693
  • EudraCT 2021-003527-14
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, France, Italy, Netherlands, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05347693. Randomized; no masking; primary purpose treatment. Start 2022-03-24 (actual); primary completion 2024-12-10 (actual). Results posted on 2025-11-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
Acronym
CONTINUITY
Condition
Hyperkalaemia
Intervention (Drug)
Sodium Zirconium Cyclosilicate (SZC)
Intervention (Drug)
Local standard of care
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct05347693
Content hash
e7b9a40c8e4d970edcb3e3b83921aa6fc06eba66161b80f0c42d432827c774ef